Overexpression of insulin-like growth factor-binding protein-2 in pterygium body fibroblasts

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 2, 2003, Pages 573-580

  Solomon, Abraham ^a   Grueterich, Martin ^a   Li, De Quan ^a   Meller, Daniel ^a   Lee, Sao Bing ^d   Tseng, Scheffer C G ^a,b,c  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c OCULAR SURFACE CENTER   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 2;

ARTICLE; COMPARATIVE STUDY; CONJUNCTIVA; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PTERYGIUM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

BLOTTING, WESTERN; CELLS, CULTURED; CONJUNCTIVA; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MIDDLE AGED; PTERYGIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0037309996     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.01-1185     Document Type: Article

References (56)

1. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-β and tumor necrosis factor-α in the pterygium. Acta Histochem (Jena). 1996;98:195-201.
2. Kawashima Y, Saika S, Yamanaka O, et al. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues. Curr Eye Res. 1998;17:445-451.
3. Di Girolamo N, McCluskey P, Lloyd A, et al. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells. Invest Ophthalmol Vis Sci. 2000;41:671-679.
4. Li D-Q, Lee S-B, Gunja-Smith Z, et al. Overexpression of collagenase (MMP-1) and stromelysin (MMP-3) by cultured pterygium head fibroblasts. Arch Ophthalmol. 2001;119:71-80.
5. Solomon A, Li D-Q, Lee S-B, Tseng SCG. Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines. Invest Ophthalmol Vis Sci. 2000;41:2154-2163.
6. Hiraoka a, Sasaguri Y, Komiya S, et al. Cell proliferation-related production of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin) by cultured human rheumatoid fibroblasts. Biochem Int. 1992;27:1083-1091.
7. Kumkumian GK, Lafyatis R, Remmers EF, et al. Platelet-derived growth factor and IL-1 interactions in rheumatoid arthritis: regulation of synoviocyte proliferation, prostaglandin production, and collagenase transcription. J Immunol. 1998;143:833-837.
8. Cohick WS, Clemmons DR. The insulin-like growth factors. Annu Rev Physiol. 1993;55:131-153.
9. Lowe WL Jr. Once is not enough: promiscuity begets diversity among the insulin-like growth factor'binding proteins. Endocrinology. 1994;135:1719-1721.
10. Baserga R, Prisco M, Hongo A. IGFs and cell growth. In: Rosenfeld RG, Roberts CT Jr, eds. The IGF System. St. Louis, MO: CV Mosby; 1999.
11. Zumkeller W, Westphal M. The IGF/IGFBP system in CNS malignancy. Mol Pathol. 2001;54:227-229.
12. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
13. Schoen TJ, Chader GJ. Insulin-like growth factors and their binding proteins in the developing eye. Prog Retin Eye Res. 1997;16:479-507.
14. Zapf J. Physiological role of the insulin-like growth factor binding proteins. Eur J Endocrinol. 1995;132:645-654.
15. Cohen P, Peehl DM, Stamey TA, et al. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993;76:1031-1035.
16. Kanety H, Kattan M, Goldberg I, et al. Increased insulin-like growth factor binding protein-2 (IGFBP-2) gene expression and protein production lead to high IGFBP-2 content in malignant ovarian cyst fluid. Br J Cancer. 1996;73:1069-1073.
17. Mishra L, Bass B, Ooi BS, et al. Role of insulin-like growth factor-I (IGF-1) receptor, IGF-I, and IGF binding protein-2 in human colorectal cancers. Growth Horm IGF Res. 1998;8:473-479.
18. Boulle N, Logie A, Gicquel C, et al. Increased levels of insulin-like growth factor II (IGF-II) and IGF- binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1998;83:1713-1720.
19. Wex H, Vorwerk P, Mohnike K, et al. Elevated serum levels of IGFBP-2 found in children suffering from acute leukaemia is accompanied by the occurrence of IGFBP-2 mRNA in the tumour clone. Br J Cancer. 1998;78:515-520.
20. Fuller GN, Rhee CH, Hess KR, et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999;59:4228-4232.
21. Tan DTH, Chee S-P, Dear KBG, Lim ASM. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol. 1997;115:1235-1240.
22. Li D-Q, Tseng SCG. Three patterns of cytokine expression potentially involved in epithelial-fibroblast interactions of human ocular surface. J Cell Physiol. 1995;163:61-79.
23. Zong Q, Schummer M, Hood L, Morris DR. Messenger RNA translation state: the second dimension of high-throughput expression screening. Proc Natl Acad Sci USA. 1999;96:10632-10636.
24. Dushku N, John MK, Schultz GS, Reid TW. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalmol. 2001;119:695-706.
25. Di Girolamo N, Coroneo MT, Wakefield D. Active matrilysin (MMP-7) in human pterygia: potential role in angiogenesis. Invest Ophthalmol Vis Sci. 2001;42:1963-8.
26. Dushku N, Reid TW. Immunohistochemical evidence that human pterygia originate from an invasion of vimentin-expressing altered limbal epithelial basal cells. Curr Eye Res. 1994;13:473-481.
27. Dushku N, Reid TNV. p53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res. 1997;16:1179-1192.
28. Chert J-K, Tsai RJF, Lin S-S. Fibroblasts isolated from human pterygia exhibit transformed cell characteristics. In Vitro Cell Dev Biol. 1994;30:243-248.
29. Spandidos DA, Sourvinos G, Kiaris H, Tsamparlakis J. Microsatellite instability and loss of heterozygosity in hmnan pterygia. Br J Ophthalmol. 1997;81:493-496.
30. Heller RA, Schena M, Chai A, et al. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA. 1997;94:2150-2155.
31. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 1994;22:5640-5648.
32. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997;82:2308-2313.
33. el Atiq F, Garrouste F, Remacle-Bonnet M, et al. Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer. 1994;57:491-497.
34. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf). 1997;46:333-342.
35. Muller HL, Oh Y, Lehrnbecher T, et al. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab. 1994;79:428-434.
36. Elmlinger MW, Deininger MH, Schuett BS, et al. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 2001;142:1652-1658.
37. Takagi H, Yoshimura N, Tanihara H, Honda Y. Insulin-like growth factor-related genes, receptors, and binding proteins in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1994;35:916-923.
38. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease: studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
39. Burren CP, Berka JL, Batch JA. Localization studies of IGFBP-2 and IGFBP-5 in the anterior compartment of the eye. Curr Eye Res. 1997;16:256-262.
40. Arnold DR, Moshayedi P, Schoen TJ, et al. Distribution of IGF-I and -II, IGF binding proteins (IGFBPs) and IGFBP mRNA in ocular fluids and tissues: potential sites of synthesis of IGFBPs in aqueous and vitreous. Exp Eye Res. 1993;56:555-565.
41. Hughes SC, Xu S, Fernihough J, et al. Tissue IGFBP-3 proteolysis: contrasting pathophysiology to that in the circulation. Prog Growth Factor Res. 1995;6:293-299.
42. Cianfarani S, Bonfanti R, Bitti ML, et al. Growth and insulin-like growth factors (IGFs) in children with insulin-dependent diabetes mellitus at the onset of disease: evidence for normal growth, age dependency of the IGF system alterations, and presence of a small (approximately 18-kilodalton) IGF-binding protein-3 fragment in serum. J Clin Endocrinol Metab. 2000;85:4162-4167.
43. Kale AS, Liu F, Hintz RL, et al. Characterization of insulin-like growth factors and their binding proteins in peritoneal dialysate. Pediatr Nephrol. 1996;10:467-473.
44. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem. 1994;269:25742-25746.
45. Fowlkes JL, Thrailkill KM, Serra DM, et al. Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res. 1995;6:255-263.
46. Co Ng LL, Lang CH, Bereket A, et al. Effect of hyperthyroidism on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in adolescent children. J Pediatr Endocrinol Metab. 2000;13:1073-1080.
47. Miraki-Moud F, Jenkins PJ, Fairclough PD, et al. Increased levels of insulin-like growth factor binding protein-2 in sera and turnouts from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol (Oxf). 2001;54:499-508.
48. Rousselle AV, Damiens C, Grimaud E, et al. Potential synergies between matrix proteins and soluble factors on resorption and proteinase activities of rabbit bone cells. Histol Histopathol. 2001; 16:727-734.
49. Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res. 1998;58:3243-3247.
50. Mira E, Manes S, Lacalle RA, et al. Insulin-like growth factor I-triggered cell migration and invasion are mediated by matrix metalloproteinase-9. Endocrinology. 1999;140:1657-1664.
51. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev. 1999;18:377-385.
52. Hough CD, Cho KR, Zonderman AB, et al. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001;61:3869-3876.
53. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev. 2001;10:243-248.
54. Zimmermann EM, Li L, Hou YT, et al. Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease. Am J Physiol. 2001;280:G1022-G1029.
55. Allen JT, Knight RA, Bloor CA, Spiteri MA. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 1999;21:693-700.
56. Okan A, Comlekci A, Akpinar H, et al. Serum concentrations of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in patients with chronic hepatitis. Scand J Gastroenterol. 2000;35:1212-1215.